Badreddin Edris - 05 Jun 2026 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Director
Issuer ticker: EWTX
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2026, 18:19:24 UTC
Prior SEC filing: 23 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/John R. Moore Attorney-in-Fact for Badreddin Edris

Key filing fact

Badreddin Edris filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 16 Jun 2026.

Key facts

This page summarizes Badreddin Edris's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Jun 2026, 18:19.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001786966 Primary reporting owner

Edris Badreddin

Relationship: Director
Address: C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature: /s/John R. Moore Attorney-in-Fact for Badreddin Edris
Signature date: 16 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +5,619
Change %
Price: $0.000000^*
Shares after: 5,619
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,619
Exercise price: $0.000000
Footnotes: F1

EWTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +8,188
Change %
Price: $0.000000^*
Shares after: 8,188
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,188
Exercise price: $35.59
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Footnote F2

100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.